Please assess the completion status of the following clinical trial:

Trial Title: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones and/or insulin within 12 weeks prior to study participation, omarigliptin and/or sitagliptin anytime

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin 25 mg (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
- Sitagliptin (Phase A) switching to Omarigliptin (Phase B) (Type: ACTIVE_COMPARATOR): Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
- Placebo (Phase A) switching to Omarigliptin (Phase B) (Type: PLACEBO_COMPARATOR): Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)

Based on this trial design, predict the completion outcome and termination type (if applicable).